![BioProcess Insider Daily BioProcess Insider Daily](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt67a005f537dd7ccc/6601b7e966ce71040a329a01/Insider-Daily-Logo.png?width=700&auto=webp&quality=80&disable=upscale)
Our BioProcess Insider editorial team is at BPI Europe 2024 to bring you some of the most pertinent coverage from across the conference hall and exhibition floor here in Vienna.
Follow our coverage throughout the event, and keep abreast of the latest industry news and views all year round by signing up at www.BioProcessInsider.com
BPI Europe Highlights
MoreUCB says it built out its internal capabilities to create a process intensified AAV production process based on perfusion after finding limitations when working with external partners.
![](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/bltbdbe29a60d1494a6/6619290bc4c327774301b6f7/Depositphotos_231329254_S.jpg?width=700&auto=webp&quality=80&disable=upscale)
With limited assets, startups must rely on CDMO partners. And working with the right ones is imperative even if it comes with a cost.
![](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt357698f7f7119f67/661953ec5082140fc3469ac7/Depositphotos_91037380_S.jpg?width=700&auto=webp&quality=80&disable=upscale)
Lab-grown fish offers a sustainable alternative to current seafood production methods but suffers many of the same manufacturing-based pain points as the biopharma industry, says cultivated fish firm BLUU.
![](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/bltc3cddd33027dc1e8/66192762131b6d71e5d1f586/WhatsApp_Image_2024-04-12_at_12.03.25.jpeg?width=700&auto=webp&quality=80&disable=upscale)
Quality and compliance, customer service levels, financials, health and safety, and environmental sustainability are key to multi-modality manufacturing success, Novartis says.
More from BPI Europe
Upstream & Downstream Processing from BPI Europe
News from BPI Events
MoreAssembling the process, equipment, CMC ecosystem, manufacturing network, and talent are the key elements driving Bayer’s allogeneic cell therapy strategy, the firm says.
![Sustainability could be opportunity to innovate, says Merck Sustainability could be opportunity to innovate, says Merck](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt5b6498fc9ab50080/658ade477b6dc6040ae494ef/Depositphotos_85669896_S.jpg?width=700&auto=webp&quality=80&disable=upscale)
The overall goal is to work towards a common way of innovating to increase sustainability measures, says firm.
![It’s not me, it’s you! Experts on when you should dump your CDMO It’s not me, it’s you! Experts on when you should dump your CDMO](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt308f9a95ad151111/658aded702b732040adc2ff4/Depositphotos_5846041_S.jpg?width=700&auto=webp&quality=80&disable=upscale)
If your CDMO is not willing to change for you then it is time to find someone else, says experts at Biotech Week Boston.
![IRA and political rhetoric harming pharma reputation and innovation, Amicus IRA and political rhetoric harming pharma reputation and innovation, Amicus](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/bltc0e2f75fbb052af1/658adedea2ec4e040725a48e/WhatsApp-Image-2023-09-20-at-08.53.31.jpeg?width=700&auto=webp&quality=80&disable=upscale)
John Crowley told a packed BWB plenary how Amicus Therapeutics is “getting back the magic of biotechnology” and “recapturing the narrative.”
From last year's BPI Europe
MoreTalent pool, logistics, and a collaborative ecosystem are three overarching reasons why your CGT firm should invest in the Netherlands.
![Expert: Synthetic promoters for transcription the ‘foundation of modern biotech' Expert: Synthetic promoters for transcription the ‘foundation of modern biotech'](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/bltbb9db85fb0c32853/658ae01f8b12ab040a9dfadd/bpi-europe-23-scaled.jpeg?width=700&auto=webp&quality=80&disable=upscale)
Synthetic biology could be used to develop a new paradigm in controlling cellular function and specificity, says a bioprocess engineer.
![Bioprocess transformation: It's not just about the tech, says expert Bioprocess transformation: It's not just about the tech, says expert](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blte433e252d8eba3a9/658ae021e9b5e3040a5d2007/fausto.jpg?width=700&auto=webp&quality=80&disable=upscale)
To implement transformation successfully in your company, you must start with the person and not with the technology, says GSK.
![Inhouse vs external capacity? Choose both, says Bayer Inhouse vs external capacity? Choose both, says Bayer](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blte2a86480da189f95/658adff76607d3040a82df3d/Depositphotos_327993332_S.jpg?width=700&auto=webp&quality=80&disable=upscale)
Inhouse and outsourcing comes with risks and positives, but according to Bayer a mixture of both capacities is needed.